HAVCR2 and breast cancer: In murine models of breast cancer, TIM‐3 expression on intratumoral cDC1 cells suppressed production of the chemokine CXCL9, a known chemoattractant for CXCR3+ T lymphocytes, and the antitumor efficacy mediated by blocking either TIM‐3 or its ligand galectin‐9 was both CD8+ T cell‐ and CXCR3‐dependent,63 suggesting a suppressive role for TIM‐3 in TIDC‐mediated recruitment of T cells into tumor tissue.